Article Versions Notes

Ziouziou H, Paris C, Benizri S, Le TK, Andrieu C, Nguyen DT, Appavoo A, Taïeb D, Brunel F, Oueslati R, et al. Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer. Pharmaceutics. 2021; 13(5):623. https://doi.org/10.3390/pharmaceutics13050623

Ziouziou, Hajer, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, and et al. 2021. "Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer" Pharmaceutics 13, no. 5: 623. https://doi.org/10.3390/pharmaceutics13050623

Ziouziou, H., Paris, C., Benizri, S., Le, T. K., Andrieu, C., Nguyen, D. T., Appavoo, A., Taïeb, D., Brunel, F., Oueslati, R., Siri, O., Camplo, M., Barthélémy, P., & Rocchi, P. (2021). Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer. Pharmaceutics, 13(5), 623. https://doi.org/10.3390/pharmaceutics13050623